Abstract:BACKGROUND:Controversy exists regarding the role of PD1 and its ligand PD-L1 in chronic hepatitis B infection. In some studies, persistent HBV infection has been attributed to high levels of PD-1 and PD-L1 expression on HBV-specific T-cells and antigen-presenting cells (APCs) respectively. Other studies revealed that the up-regulation of PD-1 and PD-L1 during an acute inflammation phase is required to offset increasing positive co-stimulatory signals to avoid severe damage by an over-vigorous immune response.METHODS:Fifteen chronic hepatitis B patients, with inflammatory flare episode, were recruited prospectively. Based on serum HBV-DNA, HBsAg load, and ALT values, inflammatory flare episode were divided into initial, climax, decline and regression phase. Blood sample and liver biopsy tissues from each individual were taken in these 4 phases respectively. Circulating and intra-hepatic PD1 and PD-L1 expression levels were monitored throughout the inflammatory flare episode by flow cytometry and immunostaining and these expression levels were related to the HBV-specific T-cell changes, expression of pro-inflammatory cytokines, HBV-DNA replication and HBV antigen load.RESULTS:]The levels of PD-1 and PD-L1 expressions were significantly up-regulated in the inflammation ascending phase, initial and climax period and in parallel with HBV-specific colon expansion. It showed increasing the level of serum ALT and decreasing the HBV-DNA loads. As the level of inflammation reduced, the circulating and intra-hepatic PD1 and circulating PD-L1 decreased progressively in concordance with serum ALT, HBV-DNA and HBsAg loads decreased except intra-hepatic PD-1 expression. Intra-hepatic PD-L1 expression did not decrease significantly during the regression phase of inflammation compared to that in prior period. The intra-hepatic PD-L1 expression remained relatively on higher level when serum HBV-DNA load and ALT decreased to approximately normal range.CONCLUSION:The relatively high level of intra-hepatic PD-L1 expression during the inflammatory regression period may contribute to constitute an immunosuppressive microenvironment, which facilitate persistent HBV infection via the inhibition of HBV-specific T cell clonal expansion.

Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection

Cellular Immune Response In Patients With Chronic Hepatitis B Virus Infection

Cytokines and Chemokines in HBV Infection

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with HBV/HCV Infection and Advanced-Stage Cancer

Safety and Efficacy of Anti-Pd-1 Inhibitors in Chinese Patients with Advanced Lung Cancer and Hepatitis B Virus Infection: a Retrospective Single-Center Study

Focus on Dysregulated Adaptive Immunity in Chronic Hepatitis B: A Promising Direction for Immunotherapy

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review

Advances in Immunotherapy for Hepatitis B Virus Associated Hepatocellular Carcinoma Patients

Dendritic cell‐based immunotherapy: A potential therapeutic option for chronic Hepatitis B virus infection

PD-1 Upregulation is Associated with HBV-specific T Cell Dysfunction in Chronic Hepatitis B Patients.

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

Expression of PD-1 on T Cells in Patients with Chronic Hepatitis B at Early Phase of Antiviral Treatment

Interplay between hepatitis B virus and the type Ⅰ interferon system and new therapeutic strategies

Longitudinal Fluctuations in PD1 and PD-L1 Expression in Association with Changes in Anti-Viral Immune Response in Chronic Hepatitis B

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis

New Insights into Hepatitis B Virus Biology and Implications for Novel Antiviral Strategies

Advances in treatment and prevention of hepatitis B

Current trends and advances in antiviral therapy for chronic hepatitis B

Emerging drugs for the treatment of hepatitis B

Advances in the Pharmacological Management of Chronic Hepatitis B

Immunotherapy for chronic hepatitis B virus infections